Researchers have found that CAR-T cells’ anti-tumor activity will increase due to the inhibition of Akt signaling during the preparation process of CAR-T cells, suggesting that the inhibition of this signaling may be another therapeutic target to enhance the anti-tumor activity of CAR-T cell therapy [73]. This evidence concerns the gene AKT1 and neoplasm.